LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Teladoc Health, Inc. to Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Teladoc Health, Inc. (“Teladoc” or the “Company”)
(NYSE:TDOC) of the February 11, 2019 deadline to seek the role of lead
plaintiff in a federal securities class action that has been filed
against the Company.

If you invested in Teladoc stock or options between March 3, 2016 and
December 5, 2018 and would like to discuss your legal rights, click
here: www.faruqilaw.com/TDOC.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Southern
District of New York on behalf of all those who purchased Teladoc
securities between March 3, 2016 and December 5, 2018 (the “Class
Period”). The case, Reiner v. Teladoc Health, Inc. et al No.
18-cv-11603 was filed on December 13, 2018.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by making false and/or misleading statements
and/or failed to disclose that: (1) Mark Hirschhorn, one of the
Company’s executives, was engaged in an inappropriate sexual
relationship with a subordinate; (2) Hirschhorn and this subordinate
engaged in insider trading to provide themselves with undue benefits;
(3) Hirschhorn caused the subordinate to receive promotions for which
she was unqualified, thereby negatively impacting the Company’s
operations; (4) the Company’s enforcement of its own purported
employment and trading policies were inadequate to prevent the foregoing
conduct.

Specifically, on December 5, 2018, the Southern Investigative Research
Foundation (“SIRF”) reported that Teladoc had allowed violations of
employment discrimination laws, sexual harassment laws, and its own
corporate governance policies to take place at the Company for years.
Additionally, SIRF stated that Teladoc’s CFO, Hirschhorn, had engaged
“in an affair with . . . an employee many levels below him on the
company’s organizational chart.”

After the publication of this article, Teladoc’s share price fell from
$59.81 per share on December 4, 2018 to a closing price of $55.81 on
December 6, 2018—a $4.00 or a 6.69% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Teladoc’s conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005848/en/